Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 47

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 47
---
 therein. The address of each of the foregoing entities and Dr. Readnour is 3835 Cleghorn Avenue, Suite 300, Nashville, Tennessee 37215.

Consists of 115,548 shares of common stock that may be acquired by Dr. Spigelman pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of 123,606 shares of common stock that may be acquired by Ms. Wong pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 405,880 shares of common stock held by Z3 Trust, of which Mr. Zakrzewski is an affiliate, (ii) 135,015 shares of common stock, and (iii) 198,606 shares of common stock that may be acquired by Mr. Zakrzewski pursuant to the exercise of stock options within 60 days of March 24, 2025.

See footnotes (3) through (13) above; also includes Sanjay Chanda, Ph.D. and Stephen Prior, Ph.D., who are executive officers but not named executive officers. Dr. Chanda owns 12,156 shares of common stock and may acquire 252,968 shares of common stock pursuant to the exercise of stock options within 60 days of March 24, 2025. Dr. Prior owns 16,467 shares of common stock and may acquire 72,396 shares of common stock pursuant to the exercise of stock options within 60 days of March 24, 2025.

<div align='center'>26

CERTAIN RELATIONSHIPS ANDRELATED PERSON TRANSACTIONS</div>

Other than compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers, the following is a description of each transaction since January 1, 2023, to which we were a party, in which:

the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and

any of our directors, nominees for director, executive officers or beneficial holders of more than 5% of any class of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.

Lucy Day is our Chief Financial Officer. Ms.